Neutropenia in pediatric solid organ transplant. (20th August 2022)

• Record Type: Journal Article
• Authors: Harshman, Lyndsay A.; Williams, Robin; Engen, Rachel M.
• Other Names: Dipchand Anne guestEditor.
• Is Part Of: Pediatric transplantation. Volume 26:Number 8(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-08-20
• Subjects: neutropenia -- pediatric -- side effects -- solid organ transplant; Transplantation of organs, tissues, etc. in children -- Periodicals; 617.95408305
• DOI: 10.1111/petr.14378
• Languages: English
• ISSNs: 1397-3142

Abstract

Abstract: Neutropenia is generally defined as an absolute neutrophil count in the circulation of less than 1500/mm 3 and occurs in up to 25%–30% of pediatric solid organ transplant recipients (SOT) within the first year after transplantation. In the SOT population, neutropenia is most often a result of drug‐induced bone marrow suppression but can also be secondary to viral infection, nutritional deficiencies, lymphoproliferative infiltrate, and inherited causes. Outcomes for patients with neutropenia vary by degree of neutropenia and type of solid organ transplant. Management of neutropenia should begin by addressing the underlying cause, including reducing or removing medications when appropriate, treating infections, and addressing nutrient deficiencies; however, consultation with an experienced pediatric hematologist and use of granulocyte colony‐stimulating factor (G‐CSF) may be helpful in some cases. Overall, data on clinical outcomes for G‐CSF use remain limited, but observational studies may support its use in patients with infections or severe neutropenia.